Compassionate use study offers AML patients continued treatment access
NCT ID NCT06572982
First seen Jan 19, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study gives a small group of people with acute myeloid leukemia (AML) continued access to an oral azacitidine tablet after they finished an earlier study. The main goal is to track any side effects and see how safe the drug is over time. About 20 participants will take the tablets and be monitored closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sheikh Shakhbout Medical City
Abu Dhabi, United Arab Emirates
Conditions
Explore the condition pages connected to this study.